By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
PreferencesDenyAccept

Cookie Preferences

Investor

Relations

Analyst Coverage

FIRM
ANALYST
Bank of America
Tazeen Ahmad
Cowen
Marc Frahm
H.C. Wainwright
Ed White
Jefferies
Nalin Tejavibulya
Needham & Company, LLC
Joey Stringer
Piper Sandler
Chris Raymond
Wedbush Securities
David Nierengarten

Inozyme Pharma, Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Inozyme Pharma, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Inozyme Pharma, Inc. or its management. Inozyme Pharma, Inc. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.

Inozyme Footer Logo to take you back to the homepage.
Inozyme is a global leader in developing therapies for rare diseases.
321 Summer Street, Suite 400 Boston, MA 02210